Fewer than a tenth of people that would benefit from weight-loss injections including Wegovy can access them, warns the global health agency as it publishes its initial recommendations on the medications.
Given more than one billion individuals worldwide now obese, it is urging increased and just availability to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"Our new guidance recognises that obesity is a chronic disease that can be treated with thorough and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major hurdles to universal access to the jabs that can aid individuals in losing substantial weight, explains the organization.
Weight-Loss Drug Scarcity
Even in the current best projected case, the supply of such drugs could only cover about 100 million people – fewer than 10% of those who need them, according to the WHO.
The guideline urges governments and firms to expand access, by approaches including licensing agreements.
The intellectual property rights on a key compound – the primary component of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Obesity Drugs Work
These medications imitate a body's own hormone to reduce digestion speed, reduce hunger and increase the sense of being full so people reduce food intake.
People commonly see weight reduction within a few weeks of commencing the once-weekly jabs.
Studies points to people may see weight return within a year of halting the medication, as their usual appetite resume.
To be carrying excess weight raises your chance for developing health problems, including type 2 diabetes, heart disease, brain attack, and specific cancers.
Obesity impacts individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.
